Combination Photoimmunotherapy and Cisplatin: Effects on Human Ovarian Cancer Ex Vivo

Linda Duska; Michael R Hamblin; Jaimie L. Miller; Tayyaba Hasan

doi:10.1093/jnci/91.18.1557

Related publications

Article2015

Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer

Dimitra Stefanou, Aristotelis Bamias, Hara Episkopou, Soterios Α. Kyrtopoulos, Maria Likka, Theodore Kalampokas, Stylianos Photiou, Nikos G. Gavalas, Petros P. Sfikakis, Meletios A Dimopoulos, Vassilis L. Souliotis

Article2008

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro

Philip O'Brien, Michael J. Davies, James Scurry, A N Smith, Caroline Barton, Michelle J. Henderson, Darren N. Saunders, Brian Gloss, Kate Patterson, Jennifer L. Clancy, Viola Heinzelmann‐Schwarz, Richard A Scolyer, Y Zeng, Elizabeth D. Williams, L Scurr, Anna DeFazio, David I. Quinn, C. K. W. Watts, Neville F. Hacker, Susan M. Henshall, R. L. Sutherland

Article2025

Nanodrug-based modulation of platelet–leukocyte interactions in ovarian cancer: a new frontier in targeted therapy

Jalal Naghinezhad, Somayeh Moradpanah, Nastaran Khodakarim, Michael R Hamblin, Hadi Rezaeeyan

Article2020

Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene

Xiaoqing Wang, Xiao Dong Xu, Guoqiang Jiang, Cuili Zhang, Likun Liu, Jian Jian Kang, Jing Wang, Lawrence Owusu, Liye Zhou, Lin Zhang, Weiling Li

Article1996

Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells.

Michael R Hamblin, Jaimie L. Miller, Tayyaba Hasan